KCI, an Acelity Company, today announced the launch of the V.A.C.
VERAFLO CLEANSE CHOICE™ Large Dressing designed for use with V.A.C.
VERAFLO™ Therapy to cleanse larger wounds with thick, fibrous exudate
and infectious material such as slough, and may be used on patients when
surgical debridement must be delayed or is not possible or appropriate.
With a unique, three-layer foam design with an array of holes, V.A.C.
VERAFLO CLEANSE CHOICE™ Dressing allows for selective wound cleansing
beyond traditional negative pressure wound therapy (NPWT) dressings, and
provides flexibility in treating wounds of various depths.
“As an industry leader, we understand that wound care is incredibly
complex and clinicians need more options – the combination of our core
V.A.C.® Therapy technology with these new dressings shows remarkable
potential for upending the traditional wound care approach, as
illustrated by a growing body of clinical data,” said R. Andrew Eckert,
President and CEO of Acelity. “Since launching V.A.C. VERAFLO CLEANSE
CHOICE™ Dressing last year, we have seen tremendous response from
clinicians with rapid adoption of the platform. Innovating for patients
and customers is a driving force for our company, and we continue
striving to revolutionize wound healing.”
V.A.C. VERAFLO™ Therapy consists of NPWT coupled with automated,
controlled delivery to and removal of topical wound treatment solutions
from the wound bed. It is unique in that it uses dressings, like CLEANSE
CHOICE™, specifically designed for instillation therapy with NPWT that
are less hydrophobic than the current V.A.C.® Therapy Dressings, to
provide improved fluid distribution and removal from the wound bed.
“Not all wounds are the same – so it is imperative to have specialized
wound care solutions to best manage and treat distinct wounds. The
V.A.C. VERAFLO CLEANSE CHOICE™ Dressing allows for targeted wound
cleansing, and has significantly changed the treatment pathway for many
of my patients, particularly those with severe wounds who might not be
candidates for surgical debridement, or who have wounds in hard-to-treat
areas,” said Luis Fernandez, M.D., Christus Trinity Mother Frances
Health System for Trauma, Tyler, TX. “Within my practice, I have seen
how the therapy can have enormous implications for lowering the total
cost of care for patients, clinicians and healthcare systems overall, by
potentially reducing the number of operating room visits, decreasing the
length of hospital stays, and helping to facilitate faster wound closure
Clinical evidence continues to demonstrate V.A.C. VERAFLO™ CLEANSE
CHOICE™ Dressing’s clinical benefits. In a retrospective analysis on 21
patients with large complex wounds using V.A.C. VERAFLO™ CLEANSE CHOICE™
Dressing, after three days, the majority of the fibrinous material and
slough present in the wound bed was removed during therapy, with the
following results: 1
About V.A.C. VERAFLO CLEANSE CHOICE™ Dressing
V.A.C. VERAFLO CLEANSE CHOICE™ Dressing is used in conjunction with
V.A.C. VERAFLO™ Therapy. Together they work quickly to cleanse
contaminated wounds, by helping to soften, solubilize, and remove
viscous exudate, wet slough, fibrin, and other infectious materials.1
The unique, three-layer design can be used for wounds with complex
geometries, including explored tunnels or undermining where the distal
aspect is not visible. The contact layer with a pattern of 1 cm holes
provides mechanical movement at the wound surface, in combination with
cyclic delivery and dwell of topical solutions. The two cover layers
without holes are designed to help capture large wound exudate before
they enter the tubing, and they also provide application options for
wounds with varying depths. For more information, visit www.VERAFLO.com.
About KCI, an Acelity Company
KCI, an Acelity Company, the most trusted brand in advanced wound care,
is committed to developing innovative healing solutions for customers
and patients across the care continuum. Our unsurpassed product
portfolio is available in more than 90 countries and delivers value
through solutions that speed healing and lead the industry in quality,
safety and customer experience. Committed to advancing the science of
healing, KCI sets the standard for leading advanced wound therapy
innovation. Headquartered in San Antonio, Texas, KCI employs nearly
5,000 people around the world.
1 Teot L, Boissiere F, Fluieraru S. Novel foam dressing using
negative pressure wound therapy with instillation to remove thick
exudate. Int Wound J 2017;14:842-848.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005476/en/